Market Place
Sourcing Support
Annora Pharma`s Generic Eltrombopag Receives Approvals in the U.S
18 Apr 2024 //
FDA
AbbVie`s Humira tops ICER`s list of drug-pricing worst offenders
17 Nov 2021 //
FIERCEPHARMA
Fostamatinib in chronic immune thrombocytopenia: Added benefit is not proven
06 Oct 2020 //
MEDICAL EXPRESS
Novartis strikes out on expanded use of eltrombopag in Europe
19 Oct 2019 //
SEEKINGAPLPHA
AZ bags two extensions in latest CHMP decisions
01 Jul 2019 //
PHARMATIMES
Can Dova take on Novartis? With its 2nd Doptelet nod and a price cut, maybe so
29 Jun 2019 //
FIERCE PHARMA
Enforcement Report - Week of May 29, 2019
29 May 2019 //
FDA
Amgen Submits SBLA For Nplate® (romiplostim)
19 Dec 2018 //
PR NEWSWIRE
Novartis scores FDA nod for new Promacta use
21 Nov 2018 //
FIERCE PHARMA
Novartis` blood disorder drug gets FDA approval for expanded use
16 Nov 2018 //
REUTERS
Who’s delaying generic competition? FDA publishes list of drugmakers
17 May 2018 //
ENDPTS
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
USFDA grants breakthrough therapy designation to Novartis` Promacta
04 Jan 2018 //
PHARMABIZ
NIH study shows Novartis drug eltrombopag as first-line therapy
20 Apr 2017 //
PHARMABIZ
Data back first-line use of Novartis’ eltrombopag in SAA
20 Apr 2017 //
PHARMA TIMES
EU approval for Revolade for children with rare blood disorder
11 Apr 2016 //
PHARMATIMES
Novartis receive EU approval for Revolade as first-in-class therapy for children
07 Apr 2016 //
CPHI ONLINE
Novartis` Revolade wins EU nod for rare blood disorder
02 Sep 2015 //
PHARMA TIMES
FDA expands use of Novartis` Promacta
25 Aug 2015 //
PHARMA TIMES
FDA clears Novartis` Promacta for paediatric ITP patients
13 Jun 2015 //
PHARMA TIMES
GSK Deal`s Done. Now, Novartis Has To Deliver On Cancer-Growth Pledge
03 Mar 2015 //
FIERCE PHARMA
Glaxo Sees Hope for Respiratory Drugs as Earnings Beat Estimates
04 Feb 2015 //
BLOOMBERG
GSK Announces US Regulatory Submission Seeking Additional Indication for Eltrombopag (Promacta™)
22 Dec 2014 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.